ERBB2 and breast cancer: The second patient was a 48-year-old woman with ER +, PgR +, HER2-negative breast cancer, previously treated with adjuvant cyclophosphamide and tamoxifen, taselisib and letrozole, adriamycin, and palliative radiation therapy to the lumbar spine.